The complaint filed against GeneDx (NASDAQ: WGS) alleges that the company issued false and misleading statements to the market throughout the specified class period. According to the court filing, these inaccuracies became apparent when the firm was forced to lower its projected full-year earnings after reporting disappointing margin performance in early 2026.
In section Releases
GeneDx Faces Securities Class Action Over Alleged Misleading Statements
Investors who purchased GeneDx Holdings Corp. stock between April 16, 2025, and May 4, 2026, are being urged to join a class action lawsuit. The litigation targets the company for alleged violations of the Securities Exchange Act, following a significant decline in adjusted gross margins during the first quarter of 2026.
The DJS Law Group is currently representing shareholders seeking to recover losses resulting from these disclosures. While the deadline for potential lead plaintiff appointments is set for August 3, 2026, the firm notes that investors do not need to assume a leadership role to participate in any eventual financial recovery. The litigation centers on whether GeneDx management failed to maintain transparency regarding the company’s financial health, thereby impacting share value.
Comments (0)
No comments yet. Be the first!